Korro Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Korro Bio, Inc. (KRRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-06
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.90%, a 11.36% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.40%, a 7.32% increase year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.10%, a 10.81% increase year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.70%, a 117.65% increase year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.30%, a 4.88% increase from fiscal 2024.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.10%, a 4.65% decline from fiscal 2023.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.30%, a 72.00% increase from fiscal 2022.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.50%, a 400.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 4.00% 10-Q · filed 2026-08-06 | |||||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-07 | |||||
| 2025-12-31 | 4.30% 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | 4.30% 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | 4.30% 10-Q · filed 2026-08-06 | |||||
| 2025-03-31 | 4.40% 10-Q · filed 2026-05-07 | |||||
| 2024-12-31 | 4.10% 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | 4.10% 10-Q · filed 2025-11-12 | |||||
| 2024-06-30 | 4.30% 10-Q · filed 2025-08-12 | |||||
| 2024-03-31 | 4.10% 10-Q · filed 2025-05-07 | |||||
| 2023-12-31 | 4.30% 10-K · filed 2025-03-18 | |||||
| 2023-09-30 | 3.60% 10-Q · filed 2024-11-12 | |||||
| 2023-06-30 | 3.60% 10-Q · filed 2024-08-13 | |||||
| 2023-03-31 | 3.70% 10-Q · filed 2024-05-14 | 3.60% 10-Q · filed 2023-05-12 | ||||
| 2022-12-31 | 2.50% 10-K · filed 2024-03-26 | 3.00% 10-K · filed 2023-03-10 | ||||
| 2022-09-30 | 2.80% 10-Q · filed 2022-11-08 | |||||
| 2022-06-30 | 2.90% 10-Q · filed 2022-08-09 | |||||
| 2022-03-31 | 1.70% 10-Q · filed 2022-05-04 | |||||
| 2021-12-31 | 0.50% 10-K · filed 2023-03-10 | |||||
| 2021-09-30 | 0.50% 10-Q · filed 2021-11-15 | |||||
| 2021-06-30 | 0.40% 10-Q · filed 2021-08-12 | |||||
| 2021-03-31 | 0.40% 10-Q · filed 2021-05-13 | |||||
| 2020-12-31 | 1.10% 10-K · filed 2022-03-15 | |||||
| 2020-09-30 | 1.30% 10-Q · filed 2020-11-16 | |||||
| 2020-06-30 | 1.40% 10-Q · filed 2020-08-12 | |||||
| 2020-03-31 | 1.50% 10-Q · filed 2020-05-14 | |||||
| 2019-12-31 | 2.00% 10-K · filed 2021-03-29 | |||||
| 2018-12-31 | 2.80% 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |